Brief: Cytodyn Files An IND And A Phase 2 Protocol With The FDA For The Treatment Of NASH With Leronlimab
04/09/2019 11:17
Sept 4 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN FILES AN IND AND A PHASE 2 PROTOCOL WITH THE FDA
FOR THE
TREATMENT OF NASH WITH LERONLIMAB
* CYTODYN INC - FILING OF AN IND AND A PHASE 2 CLINICAL
TRIAL
PROTOCOL WITH FDA FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
Source text for Eikon: ID:nGNXWYZZD
Further company coverage: CYDY.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer